These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19181785)

  • 1. Myelofibrotic transformation in essential thrombocythemia.
    Thiele J; Kvasnicka HM
    Haematologica; 2009 Mar; 94(3):431-3; author reply 433. PubMed ID: 19181785
    [No Abstract]   [Full Text] [Related]  

  • 2. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
    Hernández-Boluda JC; Pereira A; Gómez M; Boqué C; Ferrer-Marín F; Raya JM; García-Gutiérrez V; Kerguelen A; Xicoy B; Barba P; Martínez J; Luño E; Alvarez-Larrán A; Martínez-López J; Arbelo E; Besses C;
    Haematologica; 2014 Apr; 99(4):e55-7. PubMed ID: 24488561
    [No Abstract]   [Full Text] [Related]  

  • 3. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
    Barosi G; Mesa RA; Thiele J; Cervantes F; Campbell PJ; Verstovsek S; Dupriez B; Levine RL; Passamonti F; Gotlib J; Reilly JT; Vannucchi AM; Hanson CA; Solberg LA; Orazi A; Tefferi A;
    Leukemia; 2008 Feb; 22(2):437-8. PubMed ID: 17728787
    [No Abstract]   [Full Text] [Related]  

  • 4. Is bone marrow biopsy essential for the diagnosis of essential thrombocythemia?
    Tefferi A
    Leuk Lymphoma; 2006 Sep; 47(9):1724-5. PubMed ID: 17064976
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach.
    Carobbio A; Vannucchi AM; Rumi E; De Stefano V; Rambaldi A; Carli G; Randi ML; Gisslinger H; Passamonti F; Thiele J; Gangat N; Tefferi A; Barbui T
    Blood Cancer J; 2023 Jul; 13(1):115. PubMed ID: 37507408
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
    Passamonti F; Mora B; Barraco D; Maffioli M
    Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.
    Gowin K; Coakley M; Kosiorek H; Mesa R
    Haematologica; 2016 Oct; 101(10):e405-e406. PubMed ID: 27354022
    [No Abstract]   [Full Text] [Related]  

  • 8. Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.
    Schalling M; Gleiss A; Gisslinger B; Wölfler A; Buxhofer-Ausch V; Jeryczynski G; Krauth MT; Simonitsch-Klupp I; Beham-Schmid C; Thiele J; Gisslinger H
    Blood Cancer J; 2017 Dec; 7(12):643. PubMed ID: 29233975
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone marrow fibrosis and diagnosis of essential thrombocythemia.
    Thiele J; Kvasnicka HM; Vardiman JW; Orazi A; Franco V; Gisslinger H; Birgegard G; Griesshammer M; Tefferi A
    J Clin Oncol; 2009 Dec; 27(34):e220-1; author reply e222-3. PubMed ID: 19858378
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
    Loscocco GG; Antonioli E; Romano I; Vergoni F; Rotunno G; Mannelli F; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2021 Jun; 96(6):749-754. PubMed ID: 33719069
    [No Abstract]   [Full Text] [Related]  

  • 11. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.
    Thiele J; Orazi A; Kvasnicka HM; Franco V; Boveri E; Gianelli U; Gisslinger H; Passamonti F; Tefferi A; Barbui T
    Haematologica; 2012 Mar; 97(3):e5-6; discussion e7-8. PubMed ID: 22383744
    [No Abstract]   [Full Text] [Related]  

  • 12. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L; Verstovsek S
    Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?
    Spivak JL
    Leukemia; 2021 Jul; 35(7):1890-1893. PubMed ID: 33911177
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute myeloid leukemia and myelofibrosis: Simultaneous transformation of essential thrombocythemia during treatment with hydroxyurea.
    Nalluru SS; Efe O; Chen Y; Trivedi N
    J Cancer Res Ther; 2022; 18(4):1180-1182. PubMed ID: 36149183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis.
    Wanquet A; Courtier F; Guille A; Carbuccia N; Garnier S; Adélaide J; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Birnbaum D; Murati A
    Leuk Lymphoma; 2019 May; 60(5):1289-1293. PubMed ID: 30601073
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute megakaryoblastic leukaemia or acute myelofibrosis?
    Manoharan A; Islam A
    Br J Haematol; 1979 Sep; 43(1):157-8. PubMed ID: 574391
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
    Passamonti F; Rumi E; Arcaini L; Boveri E; Elena C; Pietra D; Boggi S; Astori C; Bernasconi P; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M
    Haematologica; 2008 Nov; 93(11):1645-51. PubMed ID: 18790799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.
    Barraco D; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Merli M; Pietra D; Barbui T; Rotunno G; Cazzola M; Giorgino T; Vannucchi AM; Passamonti F
    Blood Cancer J; 2018 Sep; 8(10):89. PubMed ID: 30291232
    [No Abstract]   [Full Text] [Related]  

  • 20. Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic/early primary myelofibrosis, and overt primary myelofibrosis.
    Luque Paz D; Cottin L; Lippert E; Robin JB; Bescond C; Genevieve F; Boyer F; Quintin-Roue I; Rousselet MC; Burroni B; Hunault-Berger M; Ugo V; Ianotto JC; Orvain C
    Ann Hematol; 2022 Apr; 101(4):893-896. PubMed ID: 34611719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.